Men with lower PSA levels at the start of sipuleucel T immunotherapy for metastatic castration-resistant prostate cancer (mCRPC) have better survival odds, new findings suggest. Sipuleucel T is ...

Tomasz Beer, MD Retreatment was well tolerated, with most adverse events mild to moderate in severity. CHICAGO—Retreatment with sipuleucel-T, an autologous cellular immunotherapy, is safe and may ...

Molecular Load of Pathologically Occult Metastases in Pelvic Lymph Nodes Is an Independent Prognostic Marker of Biochemical Failure After Localized Prostate Cancer Treatment A total of 127 patients ...

A new model that compares costs and outcomes of drugs used in the treatment of castrate-resistant prostate cancer has concluded that generic docetaxel and abiraterone (Zytiga) offer better value than ...

Black men with advanced prostate cancer have a greater chance of survival after immunotherapy treatment, at least in part, because of ancestral gene variants in immune responses. That connection is ...